Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc. is a U.S.-based biotechnology company focused on developing mRNA medicines and vaccines using its proprietary LUNAR delivery platform and self-amplifying RNA technology. The company’s pipeline includes therapeutic candidates for rare diseases and infectious diseases, alongside partnered vaccine programs with large pharmaceutical and government collaborators. Arcturus has not yet built a broad commercial product business; instead, it monetizes through collaboration payments, research and development funding, milestones, and government contracts. Its most visible commercialized asset is KOSTAIVE, an mRNA COVID-19 vaccine approved in Japan and Europe through partnered arrangements. The business is therefore a development-stage RNA platform company whose value depends on clinical progress, regulatory approvals, manufacturing scale-up, and partner execution.

−89,3 %

−80,2 %

−46,1 %

6.64

6.64

— Arcturus Therapeutics Holdings Inc.
%
mRNA therapeutics35% Clinical-stage RNA medicines for rare diseases and other therapeutic indications.
mRNA vaccines30% Self-amplifying mRNA vaccine candidates and partnered vaccine programs for infectious diseases.
Platform technology and delivery20% LUNAR lipid nanoparticle delivery and related enabling technology licensed to partners.
Collaboration and government funding10% R&D funding, milestones, upfront payments, and cost reimbursement from partners and agencies.
Manufacturing services5% mRNA manufacturing and process support through the ARCALIS joint venture.

Arcturus primarily sells to pharmaceutical partners, public-sector agencies, and research collaborators rather than to...

  • Pharmaceutical collaboration partnersprimary

    Companies such as CSL Seqirus and other biotech/pharma partners pay for technology rights, development services, milestones, and potential commercial access.

  • Government and public health agenciesprimary

    Agencies such as BARDA fund vaccine and countermeasure development to support pandemic preparedness and response capabilities.

  • Manufacturing and commercialization partnerssecondary

    Partners such as Meiji Seika Pharma and ARCALIS use Arcturus technology and manufacturing support to produce and commercialize approved vaccines.

  • Biotech licensees and technical support customerssecondary

    Organizations like Vinbiocare buy technical expertise and support to build mRNA manufacturing capabilities and advance clinical obligations.

  • Research collaborators and foundationssecondary

    Disease-focused groups and collaborators support early-stage programs and help fund preclinical and clinical development.

Arcturus is headquartered in the United States, but its business is structurally international because its partners,...

  • •Headquartered in the United States and listed as a U.S. biotech company
  • •Japan is a key operating base through the ARCALIS manufacturing joint venture
  • •KOSTAIVE commercial manufacturing and shipment are underway in Japan
  • •Europe matters because KOSTAIVE has received regulatory approval there
  • •U.S. government funding and clinical development remain central to the pipeline
  • •Vietnam has been part of prior technology transfer and support arrangements

Arcturus’ strategy is to convert its RNA platform into partnered and eventually commercial products while limiting...

01
Advance ARCT-032 and ARCT-810 through clinical developmentshort-term

Clinical proof-of-concept is essential to show the platform can create value in therapeutic indications beyond vaccines.

02
Commercialize partnered vaccine programsmedium-term

Approved products can generate milestones, royalties, and validation of the self-amplifying RNA platform.

03
Scale manufacturing and supply chain capabilitymedium-term

Reliable mRNA manufacturing is a prerequisite for clinical supply, regulatory approval, and commercial launch.

04
Secure non-dilutive funding and strategic collaborationsshort-term

Partner and government funding helps finance development in a capital-intensive industry with long timelines.

Arcturus faces the classic risks of a development-stage biotech company: clinical failure, regulatory delay, and the...

high

Clinical development failure

The company’s value depends on proving safety and efficacy in programs such as ARCT-032 and ARCT-810.

Scope
Pipeline programs
Materiality
high
high

Manufacturing and scale-up issues

mRNA drug substance and drug product manufacturing is technically complex and can delay trials or commercialization.

Scope
ARCALIS and contract manufacturers
Materiality
high
high

Funding and liquidity dependence

The company relies on collaboration payments, grants, and capital raises rather than product sales.

Scope
BARDA, CSL Seqirus, equity financing
Materiality
high
medium

Competitive pressure in RNA therapeutics and vaccines

Larger biotech and pharma companies can outspend Arcturus on R&D, trials, and commercialization.

Scope
RNA platform and vaccine markets
Materiality
high
medium

Government funding and policy disruption

BARDA and other public-sector programs are sensitive to budget, shutdown, and procurement changes.

Scope
U.S. federal contracts
Materiality
medium
Collaboration and grant revenue recognition
Affects reported revenue, deferred revenue, and comparability across quarters
Research and development accruals
Affects operating expenses and accrued liabilities
Stock-based compensation
Affects operating expense and non-cash dilution analysis
Contingent and contractual liabilities
Affects accrued expenses and cash flow timing

Arcus Biosciences, Inc.

RCUS · Pharmaceutical Preparations

Arcutis Biotherapeutics, Inc.

ARQT · Pharmaceutical Preparations

Arcellx, Inc.

Biological Products, (No Diagnostic Substances)

Artiva Biotherapeutics, Inc.

ARTV · Biological Products, (No Diagnostic Substances)

Atara Biotherapeutics, Inc.

ATRA · Biological Products, (No Diagnostic Substances)

PRECISION BIOSCIENCES INC

DTIL · Biological Products, (No Diagnostic Substances)

: 11/08/2026